Shang Hai Zheng Quan Bao·2026-02-27 22:57Core Viewpoint - The Hong Kong IPO market is experiencing a robust start in 2026, with over 20 companies completing IPOs and total fundraising reaching approximately 10 times that of the same period last year, indicating strong confidence in Hong Kong as an international financing platform [1][2]. Group 1: IPO Market Dynamics - The total fundraising amount for Hong Kong IPOs in 2026 has surpassed $10 billion, setting a historical high for the same period, reflecting high recognition of Hong Kong as an international financing platform [2]. - The number of companies waiting to go public continues to increase, with 488 companies currently in the queue, suggesting a sustained active IPO market [1][2]. - The structure of the IPO market is evolving, with an increase in international companies considering listings in Hong Kong, alongside a rise in large and innovative IPO projects [2]. Group 2: Financing Trends - The convertible bond market for Chinese companies is thriving, driven by the diversification of refinancing industries and products, particularly in technology and AI sectors [2][3]. - The flexibility and cost-effectiveness of products like convertible bonds are gaining acceptance among issuers, reflecting an improvement in the functionality and inclusiveness of the Hong Kong refinancing market [3]. Group 3: International Investment Interest - International long-term funds are increasingly participating in the Hong Kong equity financing market, with net inflows from overseas funds reaching $8.6 billion in January 2026, significantly higher than the previous month [4]. - High-quality global long-term funds and sovereign wealth funds are playing a crucial role as cornerstone and anchor investors, indicating strong confidence in quality Hong Kong projects [4]. Group 4: Sector-Specific Insights - The AI industry and innovative pharmaceuticals are key areas of interest for international funds, with a preference for companies that demonstrate long-term leadership in their respective sectors [5][6]. - The technology sector is evolving, with a more complete and investment-worthy ecosystem forming around AI, as various companies in the AI supply chain enter the capital market [6]. - The innovative pharmaceutical sector is maturing, with a shift in investor focus from early-stage research to clinical progress quality and commercialization capabilities [7].